New research suggests that ketamine nasal spray may prove a safe and effective treatment for refractory chronic migraine.
A study has been launched that is investigating COMP360 psilocybin therapy – an investigational new therapy – for treatment-resistant depression (TRD).
New data released by Sunstone Therapies shows positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD).
In a groundbreaking milestone for psychedelics in Europe, a cross-party MEP Action Group for the Medical Use of Psychedelics was launched at an expert roundtable on...
MP Crispin Blunt raised a point of order in the House of Commons after the UK’s Drugs Minister failed to show up for a debate on...
Subanaesthetic intravenous ketamine has been shown to be as effective and not inferior to electroconvulsive therapy (ECT) for the treatment of non-psychotic, treatment-resistant depression.
Cybin Inc.
PSYCH Symposium: London 2023 is returning on 6 July at the iconic British Museum to explore the latest challenges and opportunities in the field of psychedelic...
Lucy Scientific Discovery is partnering with non-profit organization that advocates for legal access to psilocybin therapy for Canadians, TheraPsil, to advance medical access and research.
A UK Parliamentary debate on 18 May saw crossparty calls to conduct an urgent review of the evidence for psilocybin’s current status as a Schedule 1...
With a rise in clinical research and trials into the use of psychedelic therapies for mental health, and with a number of countries changing regulations around...
The Royal College of Psychiatrists, Heroic Hearts and other leading mental health charities have written letters to the Veterans Minister and the Minister of State for...